A man in his seventies  with prolonged myasthenic crisis.
Department of Neurology, Nordland Hospital, Bodø, Norway. espen.benjaminsen@nlsh.no
Espen
E
Benjaminsen
Gunnar Waage
GW
Skjeflo
Knut
K
Dybwik
Rolf
R
Salvesen
D000368:Aged; D000588:Amines / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects; D000077206:Gabapentin; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D009157:Myasthenia Gravis / Q000150:complications* / Q000188:drug therapy; D011014:Pneumonia / Q000150:complications* / Q000188:drug therapy; D012121:Respiration, Artificial; D012131:Respiratory Insufficiency / Q000209:etiology* / Q000628:therapy; D000069283:Rituximab; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects
D000588:Amines; D000900:Anti-Bacterial Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D003509:Cyclohexanecarboxylic Acids; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D000069283:Rituximab; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D008775:Methylprednisolone